drugset
Drugs / SOF/VEL/VOX
last change Jul 2017 re-read 3 minutes ago

SOF/VEL/VOX

also known as sofosbuvir/velpatasvir/voxilaprevir
Developed for
chronic hepatitis C virus infection
Investigated by
Gilead Sciences

Trials 1

today NCT02536313 · Ph 2
201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT02536313 Jul 2015 → Mar 2016 chronic hepatitis C virus infection Gilead Sciences Completed No outcome recorded

Press releases naming this drug 5 releases

DateIssuerRelease
2017-07-28 Gilead Sciences European Commission Grants Marketing Authorization for Gilead’s Vosevi® (Sofosbuvir/Velpatasvir/Voxilaprevir) for the Treatment of All Genotypes of Chronic Hepatitis C gilead.com ↗
2017-07-18 Gilead Sciences U.S. Food and Drug Administration Approves Gilead’s Vosevi™ (Sofosbuvir/Velpatasvir/Voxilaprevir) for Re-Treatment of Adults with Chronic Hepatitis C Virus gilead.com ↗
2017-06-23 Gilead Sciences European CHMP Adopts Positive Opinion for Gilead’s Vosevi® (Sofosbuvir/Velpatasvir/Voxilaprevir) for the Treatment of All Chronic Hepatitis C Genotypes gilead.com ↗
2017-01-20 Gilead Sciences European Medicines Agency Validates Gilead’s Marketing Authorization Application for Investigational Chronic Hepatitis C Therapy Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) gilead.com ↗
2016-12-08 Gilead Sciences Gilead Submits New Drug Application to U.S. Food and Drug Administration for the Investigational Single Tablet Regimen Sofosbuvir/Velpatasvir/Voxilaprevir gilead.com ↗

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as SOF/VEL/VOX ClinicalTrials.gov intervention name — accepted as the source's own label NCT02536313 ↗
Known as sofosbuvir/velpatasvir/voxilaprevir “The primary objective of this study is to evaluate the efficacy, safety, and tolerability of the treatment with sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) fixed dose...” NCT02536313 ↗
Route Oral “400/100/100 mg FDC tablet administered orally once daily with food” NCT02536313 ↗